Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Is there progress in the treatment of high-risk myeloma?

Is there progress in the treatment of high-risk myeloma? Treatment of high-risk patients is a major challenge in multiple myeloma (MM). Median survival rates of these patients remain poor at about 2 years and there were no major improvements with the introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). This resulted in a remarkable discrepancy in the treatment results of MM, with a significant proportion of patients achieving long-term progression-free survival of >10 years (or even cure) while in patients with aggressive disease no or only minor improvements have been achieved. Current consensus statements define high-risk based on International Staging System (ISS) stage III plus the presence of cytogenetic aberrations (t(4;14) and/or del17p) and/or high lactate dehydrogenase (LDH). Regarding the treatment of high-risk patients, autologous stem cell transplantation remains the standard of care in transplant-eligible candidates. However, there is an unmet need for novel therapeutic strategies to overcome the limitations of current treatment modalities. Hence, efforts to study high-risk disease in MM were recently intensified. The ongoing search for new treatment strategies and drug targets is also reflected by the growing number of studies investigating high-risk disease. This short review aims to provide an overview about the current research landscape and recent progress in high-risk MM based on selected abstracts of the ASH 2016 meeting. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Is there progress in the treatment of high-risk myeloma?

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/is-there-progress-in-the-treatment-of-high-risk-myeloma-tQPqMgjWJ1
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0338-0
Publisher site
See Article on Publisher Site

Abstract

Treatment of high-risk patients is a major challenge in multiple myeloma (MM). Median survival rates of these patients remain poor at about 2 years and there were no major improvements with the introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). This resulted in a remarkable discrepancy in the treatment results of MM, with a significant proportion of patients achieving long-term progression-free survival of >10 years (or even cure) while in patients with aggressive disease no or only minor improvements have been achieved. Current consensus statements define high-risk based on International Staging System (ISS) stage III plus the presence of cytogenetic aberrations (t(4;14) and/or del17p) and/or high lactate dehydrogenase (LDH). Regarding the treatment of high-risk patients, autologous stem cell transplantation remains the standard of care in transplant-eligible candidates. However, there is an unmet need for novel therapeutic strategies to overcome the limitations of current treatment modalities. Hence, efforts to study high-risk disease in MM were recently intensified. The ongoing search for new treatment strategies and drug targets is also reflected by the growing number of studies investigating high-risk disease. This short review aims to provide an overview about the current research landscape and recent progress in high-risk MM based on selected abstracts of the ASH 2016 meeting.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 6, 2017

References

  • Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
    Kumar, SK; Dispenzieri, A; Lacy, MQ; Gertz, MA; Buadi, FK; Pandey, S
  • IMWG consensus on risk stratification in multiple myeloma
    Chng, WJ; Dispenzieri, A; Chim, C-S; Fonseca, R; Goldschmidt, H; Lentzsch, S
  • Survival and years of life lost in different age cohorts of patients with multiple myeloma
    Ludwig, H; Bolejack, V; Crowley, J; Bladé, J; Miguel, JS; Kyle, RA
  • Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
    Bringhen, S; Mateos, MV; Zweegman, S; Larocca, A; Falcone, AP; Oriol, A
  • The molecular classification of multiple myeloma
    Zhan, F; Huang, Y; Colla, S; Stewart, JP; Hanamura, I; Gupta, S
  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
    Sonneveld, P; Avet-Loiseau, H; Lonial, S; Usmani, S; Siegel, D; Anderson, KC
  • A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
    Shaughnessy, JD; Zhan, F; Burington, BE; Huang, Y; Colla, S; Hanamura, I
  • High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
    Paiva, B; Gutiérrez, NC; Rosiñol, L; Vídriales, M-B; Montalbán, M-Á; Martínez-López, J
  • Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
    Hose, D; Rème, T; Hielscher, T; Moreaux, J; Messner, T; Seckinger, A
  • Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
    Nowakowski, GS; Witzig, TE; Dingli, D; Tracz, MJ; Gertz, MA; Lacy, MQ
  • Clonal competition with alternating dominance in multiple myeloma
    Keats, JJ; Chesi, M; Egan, JB; Garbitt, VM; Palmer, SE; Braggio, E
  • Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
    Egan, J; Shi, CX; Tembe, W; Christoforides, A; Kurdoglu, A; Sinari, S
  • Intensification therapy with bortezomib-melphalan-prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European myeloma network (EMN02/HO95 MM trial)
    Cavo, M; Beksac, M; Dimopoulos, MA; Pantani, L; Gay, F; Hájek, R
  • Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European myeloma network (EMN02/HO95 MM trial)
    Cavo, M; Petrucci, MT; Raimondo, F; Zamagni, E; Gamberi, B; Crippa, C
  • Consolidation followed by maintenance therapy versus maintenance alone in newly diagnosed, transplant eligible patients with multiple myeloma (MM): a randomized phase 3 study of the european myeloma network (EMN02/HO95 MM trial)
    Sonneveld, P; Beksac, M; Holt, B; Dimopoulos, MA; Carella, AM; Ludwig, H
  • Bortezomib consolidation following autologous transplant equalizes the outcome for older patients with less intensive pretreatment compared to younger patients with newly diagnosed multiple myeloma
    Straka, C; Knop, S; Vogel, M; Müller, J; Kropff, M; Metzner, B
  • RVD + ASCT + lenalidomide maintenance benefits patients without high-risk cytogenetics and results in recovery of the normal plasma cell composition in bone marrow
    Silvennoinen, R; Anttila, P; Säily, M; Lundan, T; Heiskanen, J; Siitonen, T
  • Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction/consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial
    Wester, R; Holt, B; Asselbergs, E; Duin, M; Zweegman, S; Kersten, MJ
  • Final results of a phase 2 trial of extended treatment (tx) with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Krd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM)
    Zimmermann, T; Raje, NS; Vij, R; Reece, D; Berdeja, JG; Stephens, LA
  • Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of castor
    Mateos, MV; Estell, J; Barreto, W; Corradini, P; Min, CK; Medvedova, E
  • Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of pollux
    Usmani, SZ; Dimopoulos, MA; Belch, A; White, D; Benboubker, L; Cook, G
  • Daratumumab single agent and daratumumab plus pomalidomide and dexametasone in relapsed/refractory multiple myeloma: a real life retrospective evaluation
    Branca, A; Buros, A; Yoon, D; Suva, LJ; Weinhold, N; Rasche, L
  • The HIV protease inhibitor Nelfinavir in combination with bortezomib and dexamethasone (NVd) has excellent activity in patients with advanced, proteasome inhibitor-refractory multiple myeloma: a multicenter phase II trial (SAKK 39/13)
    Driessen, C; Müller, R; Novak, U; Cantoni, N; Betticher, D; Mach, N
  • Selinexor and low dose dexamethasone (sd) in patients with lenalidomide, pomalidomide, bortezomib, carfilzomib and anti-CD38 Ab refractory multiple myeloma (MM): STORM study
    Vogl, DT; Dingli, D; Cornell, RF; Huff, CA; Jagannath, S; Bhutani, D
  • Final results of phase 1 MMRC trial of selinexor, carfilzomib, and dexamethasone in relapsed/refractory multiple myeloma (RRMM)
    Jakubowiak, A; Jasielec, J; Rosenbaum, CA; Cole, CE; Chari, A; Nam, J
  • Venetoclax monotherapy for relapsed/refractory multiple myeloma: safety and efficacy results from a phase I study
    Kumar, S; Vij, R; Kaufman, JL; Mikhael, J; Facon, T; Pegourie, B
  • Venetoclax combined with bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma
    Moreau, P; Chanan-Khan, AA; Roberts, AW; Agarwal, AB; Facon, T; Kumar, S
  • Pmd-107: marizomib, pomalidomide and low dose-dexamethasone combination study in relapsed/refractory multiple myeloma (NCT02103335): full enrollment results from a phase-1 multicenter, open label study
    Spencer, A; Harrison, S; Laubach, JP; Zonder, J; Badros, AZ; Bergin, K
  • Signatures of mesenchymal cell lineages and microenvironment factors are dysregulated in high risk myeloma
    Yaccoby, S; Qu, P; Mehdi, S; Hoering, A; Epstein, J; Johnson, SK
  • Mesenchymal stem cells preconditioned with myeloma cells from high-risk patients support the growth of myeloma cells from low-risk patients
    Mehdi, S; Khan, S; Ling, W; Shelton, RS; Epstein, J; Edmondson, RD
  • Bayesian network models of multiple myeloma: drivers of high risk and durable response
    Gruber, F; Keats, JJ; McBride, K; Runge, K; Wuest, D; Hadzi, T
  • FOXM1, CDK6 and Rb dependent drug resistance and senescence in myeloma
    Gu, C; Chen, R; Jing, X; Janz, S; Yang, Y
  • Maternal embryonic leucine zipper Kinase (MELK) drives a high-risk gene network and represents an attractive novel drug target in multiple myeloma
    Bolomsky, A; Heusschen, R; Schlangen, K; Schönfelder, K; Muller, J; Schreiner, W
  • Inhibition of the epigenetic modifier EZH2 Upregulates cell cycle control genes to inhibit myeloma cell growth and overcome high-risk disease features
    Pawlyn, C; Bright, M; Buros, A; Stein, CK; Walters, Z; Aronson, L